Logo.png
PetVivo Reports Fiscal Q3 2025 Results
14 févr. 2025 15h10 HE | PetVivo Holdings, Inc.
MINNEAPOLIS, MN, US, Feb. 14, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV; OTCPINK: PETVW), a leading biomedical company delivering innovative therapeutics and medical devices for...
Picture2
PetVivo Signs Exclusive Sales and Marketing Agreement with VetStem for PrecisePRP® Canine and Equine Products
14 févr. 2025 08h00 HE | PetVivo Holdings, Inc.
MINNEAPOLIS, MN, Feb. 14, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV; OTCPINK: PETVW), a leader in innovative veterinary medical solutions, has entered into an Exclusive License...
Logo.png
PETVIVO HOLDINGS, INC. TO ANNOUNCE RESULTS FOR THE THIRD QUARTER ENDED DECEMBER 31, 2024
11 févr. 2025 10h15 HE | PetVivo Holdings, Inc.
MINNEAPOLIS, MN, US, Feb. 11, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV and OTCPINK: PETVW), an emerging biomedical device company focused on the commercialization of innovative...
NTRB Logo.png
Nutriband Inc. Announces Olympian Anastasia Nichita to Advisory Board
11 févr. 2025 09h00 HE | Nutriband Inc.
ORLANDO, Fla., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (the “Company”)(NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced World and European...
NTRB Logo.png
Nutriband Receives Notice Of Allowance For New U.S. Patent Covering Its Transdermal Abuse Deterrent Technology Aversa™
07 févr. 2025 08h45 HE | Nutriband Inc.
U.S. Patent Office issues Notice of Allowance for new patent covering Nutriband's AVERSA™ technology
Full Logo - OKYO .jpg
OKYO Pharma to Complete Enrollment of Neuropathic Corneal Pain Trial by End of Second Quarter
29 janv. 2025 08h00 HE | OKYO Pharma LTD
LONDON and NEW YORK, Jan. 29, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic...
Logo.png
PetVivo Engages Former Dechra North American President, Mike Eldred as Commercial and Operations Advisor
27 janv. 2025 09h29 HE | PetVivo Holdings, Inc.
PetVivo Board Appoints Eldred as Executive Director to Lead Company Product Commercialization and Operations MINNEAPOLIS, MN, Jan. 27, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV,...
Full Logo - OKYO .jpg
OKYO Pharma Receives $1.4 Million in Non-Dilutive Funding
22 janv. 2025 07h00 HE | OKYO Pharma LTD
LONDON and NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic...
Green and Gray.png
Dogwood Therapeutics Announces Patient Dosing in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy Induced Neuropathy (CINP) to Commence First Quarter of 2025
21 janv. 2025 09h15 HE | Dogwood Therapeutics, Inc.
ATLANTA, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biopharmaceutical company focused on advancing first-in class, non-opioid,...